Sexual Satisfaction and Quality of Life in Major Depressive Disorder Before and After Treatment With Citalopram in the STAR*D Study

IsHak, Waguih William; Christensen, Scott; Sayer, Gregory; Ha, Khanh; Li, Ning; Miller, Jamie L.; Nguyen, Jaidyn; Cohen, Robert M.

doi:10.4088/jcp.12m07933

Cited by 32 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interventions that appear in published original research and/or literature reviews, and are postulated to improve QOL include: cognitive behavioral therapy (28), future-directed therapy (29), combined psychotherapy and pharmacotherapy (30), occupational/vocational therapy (31), dopaminergic agents (32), nutrition and nutritional supplements (33), augmentation with omega-3 (34), exercise (35), meditation and yoga (36), humor (37), massage (38), and music (39). QOL interventions could also include the treatment of possible comorbid medical and psychiatric conditions (40, 41), and treatment of sexual dysfunction (42, 43). However, randomized, controlled, large sample studies need to be conducted to confirm the above interventions’ usefulness in MDD.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up

IsHak

Mirocha

James

et al. 2014

Acta Psychiatr Scand

101

View full text Add to dashboard Cite

Objective This study examines the impact of Major Depressive Disorder (MDD) and its treatment on Quality of Life (QOL). Method From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we analyzed complete data of 2,280 adult MDD outpatients at entry/exit of each level of antidepressant treatments and after 12-months of entry to follow-up. QOL was measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The proportions of patients scoring ‘within-normal’ QOL (within 10% of Q-LES-Q community-norms) and those with ‘severely-impaired’ QOL (>2SD below Q-LES-Q community-norms) were analyzed. Results Before treatment, no more than 3% of MDD patients experienced ‘within-normal’ QOL. Following treatment, statistically significant improvements were detected, however the proportion of patients achieving ‘within-normal’ QOL did not exceed 30%, with>50% of patients experiencing ‘severely-impaired’ QOL. Although remitted-patients had greater improvements compared to non-remitters, 32%-60% continued to experience reduced QOL. 12-month follow-up data revealed that the proportion of patients experiencing ‘within-normal’ QOL show a statistically significant decrease in non-remitters. Conclusion Symptom-focused treatments of MDD may leave a misleading impression that patients have recovered when, in fact, they may be experiencing ongoing QOL deficits. These findings point to the need for investigating specific interventions to ameliorate QOL in MDD.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up

IsHak

Mirocha

James

et al. 2014

Acta Psychiatr Scand

101

View full text Add to dashboard Cite

show abstract

“…Sexual dysfunction is reported to occur in 40–60% of patients with major depressive disorder (MDD), is common in both men and women (Montejo et al, 2019; Montejo, Montejo, & Baldwin, 2018; Perlis et al, 2009; Seidman, 2006), and sexual dysfunction is reported to increase the risk of the development of MDD by 130–210% (Atlantis & Sullivan, 2012; Kennedy & Rizvi, 2009; Saragoussi et al, 2017). In patients with MDD, sexual dysfunction leads to poorer outcomes, and negatively affects medication adherence (Ashton, Jamerson, Weinstein, & Wagoner, 2005; Francois, Levin, Kutscher, & Asemota, 2017; Sansone & Sansone, 2012), which impacts the response to treatment for MDD (Baldessarini & Tondo, 2019), and is associated with impaired quality of life and increased rates of depression relapse (Ishak et al, 2013; Nurnberg, 2008; Saragoussi et al, 2017; Touya, Diamand, Saragoussi, & Francois, 2017; Williams, Edin, Hogue, Fehnel, & Baldwin, 2010).…”

Section: Introductionmentioning

confidence: 99%

Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis

et al. 2020

View full text Add to dashboard Cite

Background: Sexual dysfunction is common among patients with major depressive disorder (MDD). In the CLARITY study, the safety and efficacy of adjunctive pimavanserin, an inverse agonist at 5-HT 2A receptors, were demonstrated when added to existing treatment for MDD. This analysis provides a detailed assessment of the effects of pimavanserin on sexual function from the CLARITY study. Methods: Patients with a diagnosis of MDD in a depressive episode, inadequate response to ongoing antidepressant therapy, and a Montgomery-Åsberg Depression Rating Scale total score >20 were randomized to pimavanserin 34 mg/day or placebo added to ongoing treatment with an immediate revision of all selective serotonin or serotonin-norepinephrine for 5 weeks (Stage 1), and nonresponders (<50% improvement from baseline in Hamilton Depression Rating Scale [HAMD-17]) were re-randomized for an additional 5 week (Stage 2). Effects of pimavanserin on the Massachusetts General Hospital Sexual Functioning Index (MGH-SFI) and HAMD-17 Item 14 (sexual interest) were examined. Results: Among 203 patients (51 on pimavanserin; 152 on placebo), pimavanserin demonstrated significant improvement from baseline to Week 5 on the MGH-SFI (least square [LS]mean difference −0.634, 95% confidence interval [CI] [−0.964, −0.304]; p = .0002; effect size [ES], Cohen's d: .614). Across Stages 1 and 2, the weighted LSmean difference was −0.468 (95% CI [−0.720, −0.216]; p = .0003) for pimavanserin versus placebo. Mean changes from baseline to Week 5 for MGH-SFI Items 1, 2, 3, and 5 and HAMD Item 14 were significantly (p < .05) greater with pimavanserin versus placebo. Conclusions: Adjunctive pimavanserin improved sexual function in patients with MDD. Adding pimavanserin to ongoing treatment for MDD may be especially useful for patients experiencing sexual dysfunction. K E Y W O R D S adjunctive, major depressive disorder, pimavanserin, sexual function

show abstract

“…However, the types of functional impairments due to MDD vary widely 4. Impairments due to depression affect multiple facets of life, including work productivity,5,6 social functions,7,8 sexual satisfaction,9 life satisfaction,10,11 interpersonal function,12 quality of life,13 and overall health 14. Improvement with antidepressant treatment is not just restricted to change in depression severity 15–17.…”

Section: Introductionmentioning

confidence: 99%

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder

Jha¹,

Teer²,

Minhajuddin

et al. 2017

NDT

View full text Add to dashboard Cite

BackgroundMajor depressive disorder (MDD) significantly impacts performance of both work- and nonwork-related routine daily activities. We have shown that work productivity is significantly impaired in employed MDD patients, but the extent of impairments in nonwork-related routine activities and its association with antidepressant treatment outcomes has not been established.Materials and methodsActivity impairment was measured using the sixth item of Work Productivity and Activity Impairment Scale in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial (n=665). Published norms were used to define activity impairment levels. The relationship between activity impairment and baseline sociodemographic and clinical characteristics was evaluated along with changes in activity impairment and its relationship with other clinical outcomes such as symptom severity, function, and side effect burden. Remission status at 3 and 7 months was predicted based on week 6 activity impairment level.ResultsHigher psychosocial and cognitive impairments and greater number of comorbid medical conditions were associated with greater activity impairment at baseline. Proportion of participants with severe activity impairment declined from 47.6% at baseline to 18.7% at 3 months, while mean activity impairment decreased from 57.1 at baseline to 32.8 at 3 months. During course of treatment, levels of activity impairment correlated most strongly with psychosocial function among measures of symptom severity, function, quality of life, and side effect burden. No or minimal activity impairment at week 6 was associated with two to three times higher rates of remission at 3 and 7 months as compared to moderate or severe activity impairment levels even after controlling for remission status at week 6 and select baseline variables.ConclusionDepressed patients have high levels of nonwork-related activity impairment at baseline that improves significantly with treatment and independently predicts long-term clinical outcomes. Brief systematic assessment of activity impairment during the course of antidepressant treatment can help inform clinical decision-making.

show abstract

Sexual Satisfaction and Quality of Life in Major Depressive Disorder Before and After Treatment With Citalopram in the STAR*D Study

Abstract: ClinicalTrials.gov identifier: NCT00021528.

Cited by 32 publications

References 0 publications

Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up

Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up

Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder

Contact Info

Product

Resources

About